Drugs / N7-GP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00951405 | Sep 2009 → Mar 2011 | congenital hematological disorder, hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N7-GP | “A 40K glycoPEGylated, recombinant activated factor VII (rFVIIa) bypassing agent (N7-GP) with a prolonged half-life (15 h) compared with rFVIIa was developed as a potential...” PMID 23578227 ↗ Jul 2013 |
| Modality | Protein / enzyme biologic | “A 40K glycoPEGylated, recombinant activated factor VII (rFVIIa) bypassing agent (N7-GP)” PMID 23578227 ↗ Jul 2013 |
| Route | Intravenous | “N7-GP was administered intravenously” PMID 23578227 ↗ Jul 2013 |